Galderma Group N (GALD) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.061x

Based on the latest financial reports, Galderma Group N (GALD) has a cash flow conversion efficiency ratio of 0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF475.06 Million ≈ $600.61 Million USD) by net assets (CHF7.73 Billion ≈ $9.77 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GALD equity to assets ratio to measure how much of total assets are equity-financed.

Galderma Group N - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how Galderma Group N's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Galderma Group N cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Galderma Group N Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Galderma Group N ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Axon Enterprise Inc. NASDAQ:AXON	-0.009x
KOMATSU LTD. SPONS. ADR 1 F:KOMA	N/A
Banco BTG Pactual S.A. SA:BPAC11	0.018x
Endesa SA MC:ELE	0.108x
GigaDevice Semiconductor(Beiji SHG:603986	0.035x
OTP Bank Nyrt BUD:OTP	-0.264x
PT BK CE.AS.ADR/25 RP625 F:BZG	0.041x
Commerzbank AG F:ZZMS	-0.215x

Annual Cash Flow Conversion Efficiency for Galderma Group N (2021–2024)

The table below shows the annual cash flow conversion efficiency of Galderma Group N from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Galderma Group N.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CHF7.79 Billion ≈ $9.85 Billion	CHF429.77 Million ≈ $543.34 Million	0.055x	+67.62%
2023-12-31	CHF4.52 Billion ≈ $5.71 Billion	CHF148.64 Million ≈ $187.92 Million	0.033x	+28.01%
2022-12-31	CHF4.13 Billion ≈ $5.23 Billion	CHF106.30 Million ≈ $134.39 Million	0.026x	-40.45%
2021-12-31	CHF4.14 Billion ≈ $5.24 Billion	CHF178.92 Million ≈ $226.21 Million	0.043x	--

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$52.18 Billion

CHF41.27 Billion CHF

Market Cap Rank

#732 Global

#11 in Switzerland

Share Price

CHF175.75

Change (1 day)

-2.71%

52-Week Range

CHF127.30 - CHF185.80

All Time High

CHF185.80